Sign Up Today and Learn More About TearClear Stock
Invest in or calculate the value of your shares in TearClear or other pre-IPO companies through EquityZen's platform.
TearClear Stock (TEAC)
TearClear is a pharmaceutical company that specializes in providing a disruptive eye health technology.
About TearClear Stock
Founded
2015
Headquarters
Boston, MA, US
Industries
Science and Engineering, Health Care
TearClear is a pharmaceutical company that specializes in providing a class platform of drugs that enables medication delivery to ultimately enhance patient safety and compliance by capturing preservatives before they reach the ocular surface. Founded in 2015, TearClear is headquartered in California, United States.
TearClear Press Mentions
Stay in the know about the latest news on TearClear
Glaucoma Competitive Landscape Report (Updated) | Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH
openpr • Jan 19, 2024
Ocular Hypertension Market Size and Share to Increase by ...
finance • Dec 24, 2023
Open-Angle Glaucoma Market Size and Share to Accelerate ...
prnewswire • Dec 24, 2023
TearClear Raises $22M in Series B Funding
goo • Aug 12, 2020
TearClear Taps Former Shire Executive Robert Dempsey as CEO
xconomy • Jun 01, 2020
Investors in TearClear
Discover investors in TearClear stock and explore their portfolio companies
TearClear Management
Leadership team at TearClear
Board of Director
Rick A. Heinick
Chief Scientific Officer and Co-Founder
Anuj Chauhan
Join now and verify your accreditation status to gain access to:
- TearClear current valuation
- TearClear stock price
- Available deals in TearClear and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in TearClear stock?
Accredited investors can buy pre-IPO stock in companies like TearClear through EquityZen funds. These investments are made available by existing TearClear shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell TearClear stock?
Shareholders can sell their TearClear stock through EquityZen's private company marketplace. EquityZen's network includes over 320K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
